Skip to main content
Journal cover image

In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial).

Publication ,  Journal Article
Xenogiannis, I; Rangan, BV; Uyeda, L; Banerjee, S; Edson, R; Bhatt, DL; Goldman, S; Holmes, DR; Rao, SV; Shunk, K; Mavromatis, K; Bavry, AA ...
Published in: Am J Cardiol
January 1, 2022

Saphenous vein grafts (SVGs) have high rates of in-stent restenosis (ISR). We compared the baseline clinical and angiographic characteristics of patients and lesions that did develop ISR with those who did not develop ISR during a median follow-up of 2.7 years in the DIVA study (NCT01121224). We also examined the ISR types using the Mehran classification. ISR developed in 119 out of the 575 DIVA patients (21%), with similar incidence among patients with drug-eluting stents and bare-metal stents (BMS) (21% vs 21%, p = 0.957). Patients in the ISR group were younger (67 ± 7 vs 69 ± 8 years, p = 0.04) and less likely to have heart failure (27% vs 38%, p = 0.03) and SVG lesions with Thrombolysis In Myocardial Infarction 3 flow before the intervention (77% vs 83%, p <0.01), but had a higher number of target SVG lesions (1.33 ± 0.64 vs 1.16 ± 0.42, p <0.01), more stents implanted in the target SVG lesions (1.52 ± 0.80 vs 1.31 ± 0.66, p <0.01), and longer total stent length (31.37 ± 22.11 vs 25.64 ± 17.42 mm, p = 0.01). The incidence of diffuse ISR was similar in patients who received drug-eluting-stents and BMS (57% vs 54%, p = 0.94), but BMS patients were more likely to develop occlusive restenosis (17% vs 33%, p = 0.05).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

January 1, 2022

Volume

162

Start / End Page

24 / 30

Location

United States

Related Subject Headings

  • Saphenous Vein
  • Risk Factors
  • Prosthesis Design
  • Middle Aged
  • Male
  • Humans
  • Graft Occlusion, Vascular
  • Female
  • Drug-Eluting Stents
  • Coronary Restenosis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Xenogiannis, I., Rangan, B. V., Uyeda, L., Banerjee, S., Edson, R., Bhatt, D. L., … Brilakis, E. S. (2022). In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial). Am J Cardiol, 162, 24–30. https://doi.org/10.1016/j.amjcard.2021.09.024
Xenogiannis, Iosif, Bavana V. Rangan, Lauren Uyeda, Subhash Banerjee, Robert Edson, Deepak L. Bhatt, Steven Goldman, et al. “In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial).Am J Cardiol 162 (January 1, 2022): 24–30. https://doi.org/10.1016/j.amjcard.2021.09.024.
Xenogiannis I, Rangan BV, Uyeda L, Banerjee S, Edson R, Bhatt DL, et al. In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial). Am J Cardiol. 2022 Jan 1;162:24–30.
Xenogiannis, Iosif, et al. “In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial).Am J Cardiol, vol. 162, Jan. 2022, pp. 24–30. Pubmed, doi:10.1016/j.amjcard.2021.09.024.
Xenogiannis I, Rangan BV, Uyeda L, Banerjee S, Edson R, Bhatt DL, Goldman S, Holmes DR, Rao SV, Shunk K, Mavromatis K, Ramanathan K, Bavry AA, McFalls EO, Garcia S, Thai H, Uretsky BF, Latif F, Armstrong E, Ortiz J, Jneid H, Liu J, Aggrawal K, Conner TA, Wagner T, Karacsonyi J, Ventura B, Alsleben A, Lu Y, Shih M-C, Brilakis ES. In-Stent Restenosis in Saphenous Vein Grafts (from the DIVA Trial). Am J Cardiol. 2022 Jan 1;162:24–30.
Journal cover image

Published In

Am J Cardiol

DOI

EISSN

1879-1913

Publication Date

January 1, 2022

Volume

162

Start / End Page

24 / 30

Location

United States

Related Subject Headings

  • Saphenous Vein
  • Risk Factors
  • Prosthesis Design
  • Middle Aged
  • Male
  • Humans
  • Graft Occlusion, Vascular
  • Female
  • Drug-Eluting Stents
  • Coronary Restenosis